Guggenheim Capital LLC reduced its position in shares of Acorda Therapeutics (NASDAQ:ACOR) by 21.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,109 shares of the biopharmaceutical company’s stock after selling 25,001 shares during the quarter. Guggenheim Capital LLC owned 0.20% of Acorda Therapeutics worth $1,976,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in Acorda Therapeutics by 11.9% during the third quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock worth $62,813,000 after acquiring an additional 283,091 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Acorda Therapeutics by 7.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 302,836 shares of the biopharmaceutical company’s stock worth $6,496,000 after acquiring an additional 20,148 shares in the last quarter. Bogle Investment Management L P DE bought a new stake in Acorda Therapeutics during the fourth quarter worth $5,350,000. Nationwide Fund Advisors raised its position in Acorda Therapeutics by 25.7% during the third quarter. Nationwide Fund Advisors now owns 146,207 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 29,891 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Acorda Therapeutics by 15.8% during the fourth quarter. Rhumbline Advisers now owns 108,011 shares of the biopharmaceutical company’s stock worth $2,317,000 after acquiring an additional 14,718 shares in the last quarter.

How to Become a New Pot Stock Millionaire

ACOR stock opened at $23.35 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.81 and a current ratio of 3.07. Acorda Therapeutics has a 52 week low of $13.60 and a 52 week high of $29.60. The stock has a market capitalization of $1,095.44, a P/E ratio of 22.45 and a beta of 1.58.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($0.27). Acorda Therapeutics had a negative net margin of 37.97% and a negative return on equity of 4.88%. The business had revenue of $188.40 million during the quarter, compared to analyst estimates of $171.70 million. During the same quarter last year, the company posted $0.05 earnings per share. The company’s revenue was up 34.0% on a year-over-year basis. analysts predict that Acorda Therapeutics will post -0.94 EPS for the current year.

In related news, insider David Lawrence sold 31,000 shares of the company’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $27.58, for a total value of $854,980.00. Following the transaction, the insider now directly owns 5,275 shares in the company, valued at $145,484.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.90% of the company’s stock.

Several equities analysts have commented on ACOR shares. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Acorda Therapeutics in a report on Monday, April 2nd. Oppenheimer reiterated a “hold” rating on shares of Acorda Therapeutics in a report on Wednesday, March 21st. Zacks Investment Research upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. BidaskClub downgraded shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 28th. Finally, ValuEngine upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 17th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $21.83.

TRADEMARK VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2018/04/17/guggenheim-capital-llc-has-1-98-million-holdings-in-acorda-therapeutics-acor.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.